Treatment of Rheumatoid Arthritis with Humanized Anti-Interkeukin-6 Receptor Antibody~Tocilizmab (TCZ) is considered as being one of the first options when introducing a biological agent.
Bibbo, C., Goidberg, J. W.: Infections and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis-alpha inhibition therapy. Foot Ancle Int., 25: 331-335, 2004.
Bongartz, T., Sutton, A. J., Sweeting, M. J. et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: system atic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, 295: 2275-2285, 2006.
Giles, J. T., Bartlett, S. J., Gelbeer, A. C., et al.: Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum., 55: 333-337, 2006.
Kanbe, K., Inoue, K.: Efficacy of arth roscopic synovectomy for the effect attenuation cases of infliximab in rheumatoid arthritis. Clin. Rheumatol., 25: 877-881, 2006.